This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
trusted source
proofread
Anti-obesity medications may affect survival in people with knee or hip osteoarthritis
New research published in Arthritis & Rheumatology suggests that for people overweight or with obesity who also have knee or hip osteoarthritis, a slow-to-moderate—but not fast—rate of weight loss caused by anti-obesity medications may lower their risk of premature death.
Among 6,524 participants with knee or hip osteoarthritis who were taking orlistat, sibutramine, or rimonabant, the five-year death rate was 5.3%, 4.0%, and 5.4% for the "weight gain/stable," "slow-to-moderate weight loss," and "fast weight loss" groups, respectively. Compared with the "weight gain/stable" group," the risk of death was 28% lower for the "slow-to-moderate weight loss" group and only 1% lower for the "fast weight loss" arm.
"A slow-to-moderate rate of weight loss induced by anti-obesity medications may lower the risk of death in overweight/obese people with knee/hip osteoarthritis," said first author Jie Wei, Ph.D., of Xiangya Hospital, Central South University, in China.
More information: Jie Wei et al, Weight Loss Induced by Antiobesity Medications and All‐Cause Mortality Among Patients With Knee or Hip Osteoarthritis, Arthritis & Rheumatology (2023). DOI: 10.1002/art.42754
